Hannah K. Weir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hannah K. Weir has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
Trevor D. Thompson
Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, USA
6 shared publicationsChristopher J. Johnson
Cancer Data Registry of Idaho, Idaho Hospital Association, Boise, Idaho
5 shared publications- Mary C. White
Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, USA
5 shared publications - Sarah Jane Henley
Division of Cancer Prevention and Control National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention Atlanta Georgia USA
5 shared publications Claudia Allemani
London School of Hygiene & Tropical Medicine
4 shared publicationsLisa C. Richardson
Division of Cancer Prevention and Control National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention Atlanta Georgia
4 shared publications
Latest Publications
- Open Access
- 9 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 43 (1) , 87-99
Pancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD‐3 study
Background: Survival from pancreatic cancer is low worldwide. In the US, the 5‐year relative survival has been slightly higher for women, whites and younger patients than for their counterparts, and differences in age and stage at diagnosis [Corrections added Nov 16, 2022, after first online publication: a new affiliation is added to Maja Nikšić] may contribute to this pattern. We aimed to examine trends in survival by race, stage, age and sex for adults (15‐99 years) diagnosed with pancreatic cancer in the US. Methods: This population‐based study included 399,427 adults registered with pancreatic cancer in 41 US state cancer registries during 2001‐2014, with follow‐up to December 31, 2014. We estimated age‐specific and age‐standardized net survival at 1 and 5 years. Results: Overall, 12.3% of patients were blacks, and 84.2% were whites. About 9.5% of patients were diagnosed with localized disease, but 50.5% were diagnosed at an advanced stage; slightly more among blacks, mainly among men. No substantial changes were seen over time (2001‐2003, 2004‐2008, 2009‐2014). In general, 1‐year net survival was higher in whites than in blacks (26.1% vs . 22.1% during 2001‐2003, 35.1% vs . 31.4% during 2009‐2014). This difference was particularly evident among patients with localized disease (49.6% in whites vs . 44.6% in blacks during 2001‐2003, 60.1% vs . 55.3% during 2009‐2014). The survival gap between blacks and whites with localized disease was persistent at 5 years after diagnosis, and it widened over time (from 24.0% vs . 21.3% during 2001‐2003 to 39.7% vs . 31.0% during 2009‐2014). The survival gap was wider among men than among women. Conclusions: Gaps in 1‐ and 5‐year survival between blacks and whites were persistent throughout 2001‐2014, especially for patients diagnosed with a localized tumor, for which surgery is currently the only treatment modality with the potential for cure.
- 9 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 43 (1) , 87-99
Open AccessPancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD‐3 study
Background: Survival from pancreatic cancer is low worldwide. In the US, the 5‐year relative survival has been slightly higher for women, whites and younger patients than for their counterparts, and differences in age and stage at diagnosis [Corrections added Nov 16, 2022, after first online publication: a new affiliation is added to Maja Nikšić] may contribute to this pattern. We aimed to examine trends in survival by race, stage, age and sex for adults (15‐99 years) diagnosed with pancreatic cancer in the US. Methods: This population‐based study included 399,427 adults registered with pancreatic cancer in 41 US state cancer registries during 2001‐2014, with follow‐up to December 31, 2014. We estimated age‐specific and age‐standardized net survival at 1 and 5 years. Results: Overall, 12.3% of patients were blacks, and 84.2% were whites. About 9.5% of patients were diagnosed with localized disease, but 50.5% were diagnosed at an advanced stage; slightly more among blacks, mainly among men. No substantial changes were seen over time (2001‐2003, 2004‐2008, 2009‐2014). In general, 1‐year net survival was higher in whites than in blacks (26.1% vs . 22.1% during 2001‐2003, 35.1% vs . 31.4% during 2009‐2014). This difference was particularly evident among patients with localized disease (49.6% in whites vs . 44.6% in blacks during 2001‐2003, 60.1% vs . 55.3% during 2009‐2014). The survival gap between blacks and whites with localized disease was persistent at 5 years after diagnosis, and it widened over time (from 24.0% vs . 21.3% during 2001‐2003 to 39.7% vs . 31.0% during 2009‐2014). The survival gap was wider among men than among women. Conclusions: Gaps in 1‐ and 5‐year survival between blacks and whites were persistent throughout 2001‐2014, especially for patients diagnosed with a localized tumor, for which surgery is currently the only treatment modality with the potential for cure.
- Open Access
- 29 June 2022
- Published by Springer Nature in Cancer Causes & Control
- Vol. 33 (8) , 1121-1124
Risk of clear-cell adenocarcinoma of the vagina and cervix among US women with potential exposure to diethylstilbestrol in utero
Purpose Women exposed to diethylstilbestrol (DES) in utero were at elevated risk of clear-cell adenocarcinoma of the vagina and cervix (CCA) as young women. Previous research suggested that this elevated risk of CCA may persist into adulthood. We extended a published analysis to measure CCA risk as these women aged. Methods Standardized incidence ratios (SIR) compared CCA risk among women born from 1947 through 1971 (the DES-era) to CCA risk among the comparison group of women born prior to 1947, using registry data that covered the US population. Results Incidence rates of CCA among both cohorts increased with age. Among the DES-era birth cohort, higher rates of CCA were observed across all age groups except 55–59 years. SIR estimates had wide confidence intervals that often included the null value. Conclusions Results are consistent with prior research and suggest an elevated risk of CCA in midlife and at older ages among women exposed in utero to DES. These results highlight unresolved issues regarding cancer risk among aging DES daughters and appropriate screening guidance. The examination of population-based cancer surveillance data may be a useful tool for monitoring trends in the incidence of other rare cancers over time among specific birth cohorts.
- 29 June 2022
- Published by Springer Nature in Cancer Causes & Control
- Vol. 33 (8) , 1121-1124
Open AccessRisk of clear-cell adenocarcinoma of the vagina and cervix among US women with potential exposure to diethylstilbestrol in utero
Purpose Women exposed to diethylstilbestrol (DES) in utero were at elevated risk of clear-cell adenocarcinoma of the vagina and cervix (CCA) as young women. Previous research suggested that this elevated risk of CCA may persist into adulthood. We extended a published analysis to measure CCA risk as these women aged. Methods Standardized incidence ratios (SIR) compared CCA risk among women born from 1947 through 1971 (the DES-era) to CCA risk among the comparison group of women born prior to 1947, using registry data that covered the US population. Results Incidence rates of CCA among both cohorts increased with age. Among the DES-era birth cohort, higher rates of CCA were observed across all age groups except 55–59 years. SIR estimates had wide confidence intervals that often included the null value. Conclusions Results are consistent with prior research and suggest an elevated risk of CCA in midlife and at older ages among women exposed in utero to DES. These results highlight unresolved issues regarding cancer risk among aging DES daughters and appropriate screening guidance. The examination of population-based cancer surveillance data may be a useful tool for monitoring trends in the incidence of other rare cancers over time among specific birth cohorts.
- Top Cited PapersOpen Access
- 10 June 2021
- Published by Centers for Disease Control and Prevention - Preventing Chronic Disease in Preventing Chronic Disease
- Vol. 18, E59
Cancer Incidence Projections in the United States Between 2015 and 2050
Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. PCD provides an open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention.
- 10 June 2021
- Published by Centers for Disease Control and Prevention - Preventing Chronic Disease in Preventing Chronic Disease
- Vol. 18, E59
Top Cited PapersOpen AccessCancer Incidence Projections in the United States Between 2015 and 2050
Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. PCD provides an open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention.
Pediatric cancer mortality and survival in the United States, 2001‐2016
Background: Although pediatric cancer mortality and survival have improved in the United States over the past 40 years, differences exist by age, race/ethnicity, cancer site, and economic status. To assess progress, this study examined recent mortality and survival data for individuals younger than 20 years.Methods: Age‐adjusted death rates were calculated with the National Vital Statistics System for 2002‐2016. Annual percent changes (APCs) and average annual percent changes (AAPCs) were calculated with joinpoint regression. Five‐year relative survival was calculated on the basis of National Program of Cancer Registries data for 2001‐2015. Death rates and survival were estimated overall and by sex, 5‐year age group, race/ethnicity, cancer type, and county‐based economic markers.Results: Death rates decreased during 2002‐2016 (AAPC, –1.5), with steeper declines during 2002‐2009 (APC, –2.6), and then plateaued (APC, –0.4). Leukemia and brain cancer were the most common causes of death from pediatric cancer, and brain cancer surpassed leukemia in 2011. Death rates decreased for leukemia and lymphoma but were unchanged for brain, bone, and soft‐tissue cancers. From 2001‐2007 to 2008‐2015, survival improved from 82.0% to 85.1%. Survival was highest in both periods among females, those aged 15 to 19 years, non‐Hispanic Whites, and those in counties in the top 25% by economic status. Survival improved for leukemias, lymphomas, and brain cancers but plateaued for bone and soft‐tissue cancers.Conclusions: Although overall death rates have decreased and survival has increased, differences persist by sex, age, race/ethnicity, cancer type, and economic status. Improvements in pediatric cancer outcomes may depend on improving therapies, access to care, and supportive and long‐term care.
Pediatric cancer mortality and survival in the United States, 2001‐2016
Background: Although pediatric cancer mortality and survival have improved in the United States over the past 40 years, differences exist by age, race/ethnicity, cancer site, and economic status. To assess progress, this study examined recent mortality and survival data for individuals younger than 20 years.Methods: Age‐adjusted death rates were calculated with the National Vital Statistics System for 2002‐2016. Annual percent changes (APCs) and average annual percent changes (AAPCs) were calculated with joinpoint regression. Five‐year relative survival was calculated on the basis of National Program of Cancer Registries data for 2001‐2015. Death rates and survival were estimated overall and by sex, 5‐year age group, race/ethnicity, cancer type, and county‐based economic markers.Results: Death rates decreased during 2002‐2016 (AAPC, –1.5), with steeper declines during 2002‐2009 (APC, –2.6), and then plateaued (APC, –0.4). Leukemia and brain cancer were the most common causes of death from pediatric cancer, and brain cancer surpassed leukemia in 2011. Death rates decreased for leukemia and lymphoma but were unchanged for brain, bone, and soft‐tissue cancers. From 2001‐2007 to 2008‐2015, survival improved from 82.0% to 85.1%. Survival was highest in both periods among females, those aged 15 to 19 years, non‐Hispanic Whites, and those in counties in the top 25% by economic status. Survival improved for leukemias, lymphomas, and brain cancers but plateaued for bone and soft‐tissue cancers.Conclusions: Although overall death rates have decreased and survival has increased, differences persist by sex, age, race/ethnicity, cancer type, and economic status. Improvements in pediatric cancer outcomes may depend on improving therapies, access to care, and supportive and long‐term care.
- Open Access
Annual report to the nation on the status of cancer, part II: Progress toward Healthy People 2020 objectives for 4 common cancers
Background: The Centers for Disease Control and Prevention, the American Cancer Society, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States and to address a special topic of interest. Part I of this report focuses on national cancer statistics, and part 2 characterizes progress in achieving select Healthy People 2020 cancer objectives. Methods: For this report, the authors selected objectives—including death rates, cancer screening, and major risk factors—related to 4 common cancers (lung, colorectal, female breast, and prostate). Baseline values, recent values, and the percentage change from baseline to recent values were examined overall and by select sociodemographic characteristics. Data from national surveillance systems were obtained from the Healthy People 2020 website. Results: Targets for death rates were met overall and in most sociodemographic groups, but not among males, blacks, or individuals in rural areas, although these groups did experience larger decreases in rates compared with other groups. During 2007 through 2017, cancer death rates decreased 15% overall, ranging from −4% (rural) to −22% (metropolitan). Targets for breast and colorectal cancer screening were not yet met overall or in any sociodemographic groups except those with the highest educational attainment, whereas lung cancer screening was generally low (<10%). Targets were not yet met overall for cigarette smoking, recent smoking cessation, excessive alcohol use, or obesity but were met for secondhand smoke exposure and physical activity. Some sociodemographic groups did not meet targets or had less improvement than others toward reaching objectives. Conclusions: Monitoring trends in cancer risk factors, screening test use, and mortality can help assess the progress made toward decreasing the cancer burden in the United States. Although many interventions to reduce cancer risk factors and promote healthy behaviors are proven to work, they may not be equitably applied or work well in every community. Implementing cancer prevention and control interventions that are sustainable, focused, and culturally appropriate may boost success in communities with the greatest need, ensuring that all Americans can access a path to long, healthy, cancer‐free lives.
Open AccessAnnual report to the nation on the status of cancer, part II: Progress toward Healthy People 2020 objectives for 4 common cancers
Background: The Centers for Disease Control and Prevention, the American Cancer Society, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States and to address a special topic of interest. Part I of this report focuses on national cancer statistics, and part 2 characterizes progress in achieving select Healthy People 2020 cancer objectives. Methods: For this report, the authors selected objectives—including death rates, cancer screening, and major risk factors—related to 4 common cancers (lung, colorectal, female breast, and prostate). Baseline values, recent values, and the percentage change from baseline to recent values were examined overall and by select sociodemographic characteristics. Data from national surveillance systems were obtained from the Healthy People 2020 website. Results: Targets for death rates were met overall and in most sociodemographic groups, but not among males, blacks, or individuals in rural areas, although these groups did experience larger decreases in rates compared with other groups. During 2007 through 2017, cancer death rates decreased 15% overall, ranging from −4% (rural) to −22% (metropolitan). Targets for breast and colorectal cancer screening were not yet met overall or in any sociodemographic groups except those with the highest educational attainment, whereas lung cancer screening was generally low (<10%). Targets were not yet met overall for cigarette smoking, recent smoking cessation, excessive alcohol use, or obesity but were met for secondhand smoke exposure and physical activity. Some sociodemographic groups did not meet targets or had less improvement than others toward reaching objectives. Conclusions: Monitoring trends in cancer risk factors, screening test use, and mortality can help assess the progress made toward decreasing the cancer burden in the United States. Although many interventions to reduce cancer risk factors and promote healthy behaviors are proven to work, they may not be equitably applied or work well in every community. Implementing cancer prevention and control interventions that are sustainable, focused, and culturally appropriate may boost success in communities with the greatest need, ensuring that all Americans can access a path to long, healthy, cancer‐free lives.
- Top Cited PapersOpen Access
Annual report to the nation on the status of cancer, part I: National cancer statistics
Background: The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States. Methods: Data on new cancer diagnoses during 2001 through 2016 were obtained from the Centers for Disease Control and Prevention‐funded and National Cancer Institute‐funded population‐based cancer registry programs and compiled by the North American Association of Central Cancer Registries. Data on cancer deaths during 2001 through 2017 were obtained from the National Center for Health Statistics' National Vital Statistics System. Trends in incidence and death rates for all cancers combined and for the leading cancer types by sex, racial/ethnic group, and age were estimated by joinpoint analysis and characterized by the average annual percent change during the most recent 5 years (2012‐2016 for incidence and 2013‐2017 for mortality). Results: Overall, cancer incidence rates decreased 0.6% on average per year during 2012 through 2016, but trends differed by sex, racial/ethnic group, and cancer type. Among males, cancer incidence rates were stable overall and among non‐Hispanic white males but decreased in other racial/ethnic groups; rates increased for 5 of the 17 most common cancers, were stable for 7 cancers (including prostate), and decreased for 5 cancers (including lung and bronchus [lung] and colorectal). Among females, cancer incidence rates increased during 2012 to 2016 in all racial/ethnic groups, increasing on average 0.2% per year; rates increased for 8 of the 18 most common cancers (including breast), were stable for 6 cancers (including colorectal), and decreased for 4 cancers (including lung). Overall, cancer death rates decreased 1.5% on average per year during 2013 to 2017, decreasing 1.8% per year among males and 1.4% per year among females. During 2013 to 2017, cancer death rates decreased for all cancers combined among both males and females in each racial/ethnic group, for 11 of the 19 most common cancers among males (including lung and colorectal), and for 14 of the 20 most common cancers among females (including lung, colorectal, and breast). The largest declines in death rates were observed for melanoma of the skin (decreasing 6.1% per year among males and 6.3% among females) and lung (decreasing 4.8% per year among males and 3.7% among females). Among children younger than 15 years, cancer incidence rates increased an average of 0.8% per year during 2012 to 2016, and cancer death rates decreased an average of 1.4% per year during 2013 to 2017. Among adolescents and young adults aged 15 to 39 years, cancer incidence rates increased an average of 0.9% per year during 2012 to 2016, and cancer death rates decreased an average of 1.0% per year during 2013 to 2017. Conclusions: Although overall cancer death rates continue to decline, incidence rates are leveling off among males and are increasing slightly among females. These trends reflect population changes in cancer risk factors, screening test use, diagnostic practices, and treatment advances. Many cancers can be prevented or treated effectively if they are found early. Population‐based cancer incidence and mortality data can be used to inform efforts to decrease the cancer burden in the United States and regularly monitor progress toward goals.
Top Cited PapersOpen AccessAnnual report to the nation on the status of cancer, part I: National cancer statistics
Background: The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States. Methods: Data on new cancer diagnoses during 2001 through 2016 were obtained from the Centers for Disease Control and Prevention‐funded and National Cancer Institute‐funded population‐based cancer registry programs and compiled by the North American Association of Central Cancer Registries. Data on cancer deaths during 2001 through 2017 were obtained from the National Center for Health Statistics' National Vital Statistics System. Trends in incidence and death rates for all cancers combined and for the leading cancer types by sex, racial/ethnic group, and age were estimated by joinpoint analysis and characterized by the average annual percent change during the most recent 5 years (2012‐2016 for incidence and 2013‐2017 for mortality). Results: Overall, cancer incidence rates decreased 0.6% on average per year during 2012 through 2016, but trends differed by sex, racial/ethnic group, and cancer type. Among males, cancer incidence rates were stable overall and among non‐Hispanic white males but decreased in other racial/ethnic groups; rates increased for 5 of the 17 most common cancers, were stable for 7 cancers (including prostate), and decreased for 5 cancers (including lung and bronchus [lung] and colorectal). Among females, cancer incidence rates increased during 2012 to 2016 in all racial/ethnic groups, increasing on average 0.2% per year; rates increased for 8 of the 18 most common cancers (including breast), were stable for 6 cancers (including colorectal), and decreased for 4 cancers (including lung). Overall, cancer death rates decreased 1.5% on average per year during 2013 to 2017, decreasing 1.8% per year among males and 1.4% per year among females. During 2013 to 2017, cancer death rates decreased for all cancers combined among both males and females in each racial/ethnic group, for 11 of the 19 most common cancers among males (including lung and colorectal), and for 14 of the 20 most common cancers among females (including lung, colorectal, and breast). The largest declines in death rates were observed for melanoma of the skin (decreasing 6.1% per year among males and 6.3% among females) and lung (decreasing 4.8% per year among males and 3.7% among females). Among children younger than 15 years, cancer incidence rates increased an average of 0.8% per year during 2012 to 2016, and cancer death rates decreased an average of 1.4% per year during 2013 to 2017. Among adolescents and young adults aged 15 to 39 years, cancer incidence rates increased an average of 0.9% per year during 2012 to 2016, and cancer death rates decreased an average of 1.0% per year during 2013 to 2017. Conclusions: Although overall cancer death rates continue to decline, incidence rates are leveling off among males and are increasing slightly among females. These trends reflect population changes in cancer risk factors, screening test use, diagnostic practices, and treatment advances. Many cancers can be prevented or treated effectively if they are found early. Population‐based cancer incidence and mortality data can be used to inform efforts to decrease the cancer burden in the United States and regularly monitor progress toward goals.
- Open Access
- 1 March 2020
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 58 (3) , 453-456
Five-Year U.S. Trends in the North American Cancer Survival Index, 2005–2014
- 1 March 2020
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 58 (3) , 453-456
Open AccessFive-Year U.S. Trends in the North American Cancer Survival Index, 2005–2014
- 1 January 2020
- Vol. 47 (3) , 150-160
Cancer Incidence in Older Adults in the United States: Characteristics, Specificity, and Completeness of the Data.
The number of cancer cases in the United States continues to grow as the number of older adults increases. Accurate, reliable and detailed incidence data are needed to respond effectively to the growing human costs of cancer in an aging population. The purpose of this study was to examine the characteristics of incident cases and evaluate the impact of death-certificate-only (DCO) cases on cancer incidence rates in older adults. Using data from 47 cancer registries and detailed population estimates from the Surveillance, Epidemiology and End Results (SEER) Program, we examined reporting sources, methods of diagnosis, tumor characteristics, and calculated age-specific incidence rates with and without DCO cases in adults aged 65 through ≥95 years, diagnosed 2011 through 2015, by sex and race/ethnicity. The percentage of cases (all cancers combined) reported from a hospital decreased from 90.6% (ages 65-69 years) to 69.1% (ages ≥95 years) while the percentage of DCO cases increased from 1.1% to 19.6%. Excluding DCO cases, positive diagnostic confirmation decreased as age increased from 96.8% (ages 65-69 years) to 69.2% (ages ≥95 years). Compared to incidence rates that included DCO cases, rates in adults aged ≥95 years that excluded DCO cases were 41.5% lower in Black men with prostate cancer and 29.2% lower in Hispanic women with lung cancer. Loss of reported tumor specificity with age is consistent with fewer hospital reports. However, the majority of cancers diagnosed in older patients, including those aged ≥95 years, were positively confirmed and were reported with known site, histology, and stage information. The high percentage of DCO cases among patients aged ≥85 years suggests the need to explore additional sources of follow-back to help possibly identify an earlier incidence report. Interstate data exchange following National Death Index linkages may help registries identify and remove erroneous DCO cases from their databases.
- 1 January 2020
- Vol. 47 (3) , 150-160
Cancer Incidence in Older Adults in the United States: Characteristics, Specificity, and Completeness of the Data.
The number of cancer cases in the United States continues to grow as the number of older adults increases. Accurate, reliable and detailed incidence data are needed to respond effectively to the growing human costs of cancer in an aging population. The purpose of this study was to examine the characteristics of incident cases and evaluate the impact of death-certificate-only (DCO) cases on cancer incidence rates in older adults. Using data from 47 cancer registries and detailed population estimates from the Surveillance, Epidemiology and End Results (SEER) Program, we examined reporting sources, methods of diagnosis, tumor characteristics, and calculated age-specific incidence rates with and without DCO cases in adults aged 65 through ≥95 years, diagnosed 2011 through 2015, by sex and race/ethnicity. The percentage of cases (all cancers combined) reported from a hospital decreased from 90.6% (ages 65-69 years) to 69.1% (ages ≥95 years) while the percentage of DCO cases increased from 1.1% to 19.6%. Excluding DCO cases, positive diagnostic confirmation decreased as age increased from 96.8% (ages 65-69 years) to 69.2% (ages ≥95 years). Compared to incidence rates that included DCO cases, rates in adults aged ≥95 years that excluded DCO cases were 41.5% lower in Black men with prostate cancer and 29.2% lower in Hispanic women with lung cancer. Loss of reported tumor specificity with age is consistent with fewer hospital reports. However, the majority of cancers diagnosed in older patients, including those aged ≥95 years, were positively confirmed and were reported with known site, histology, and stage information. The high percentage of DCO cases among patients aged ≥85 years suggests the need to explore additional sources of follow-back to help possibly identify an earlier incidence report. Interstate data exchange following National Death Index linkages may help registries identify and remove erroneous DCO cases from their databases.
- Open Access
Lung cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study
BACKGROUND: Results from the second CONCORD study (CONCORD‐2) indicated that 5‐year net survival for lung cancer was low (range, 10%‐20%) between 1995 and 2009 in most countries, including the United States, which was at the higher end of this range.METHODS: Data from CONCORD‐2 were used to analyze net survival among patients with lung cancer (aged 15‐99 years) who were diagnosed in 37 states covering 80% of the US population. Survival was corrected for background mortality using state‐specific and race‐specific life tables and age‐standardized using International Cancer Survival Standard weights. Net survival was estimated for patients diagnosed between 2001 and 2003 and between 2004 and 2009 at 1, 3, and 5 years after diagnosis by race (all races, black, and white); Surveillance, Epidemiology, and End Results Summary Stage 2000; and US state.RESULTS: Five‐year net survival increased from 16.4% (95% confidence interval, 16.3%‐16.5%) for patients diagnosed 2001‐2003 to 19.0% (18.8%‐19.1%) for those diagnosed 2004‐2009, with increases in most states and among both blacks and whites. Between 2004 and 2009, 5‐year survival was lower among blacks (14.9%) than among whites (19.4%) and ranged by state from 14.5% to 25.2%.CONCLUSIONS: Lung cancer survival improved slightly between the periods 2001‐2003 and 2004‐2009 but was still low, with variation between states, and persistently lower survival among blacks than whites. Efforts to control well established risk factors would be expected to have the greatest impact on reducing the burden of lung cancer, and efforts to ensure that all patients receive timely and appropriate treatment should reduce the differences in survival by race and state. Cancer 2017;123:5079‐99. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Open AccessLung cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study
BACKGROUND: Results from the second CONCORD study (CONCORD‐2) indicated that 5‐year net survival for lung cancer was low (range, 10%‐20%) between 1995 and 2009 in most countries, including the United States, which was at the higher end of this range.METHODS: Data from CONCORD‐2 were used to analyze net survival among patients with lung cancer (aged 15‐99 years) who were diagnosed in 37 states covering 80% of the US population. Survival was corrected for background mortality using state‐specific and race‐specific life tables and age‐standardized using International Cancer Survival Standard weights. Net survival was estimated for patients diagnosed between 2001 and 2003 and between 2004 and 2009 at 1, 3, and 5 years after diagnosis by race (all races, black, and white); Surveillance, Epidemiology, and End Results Summary Stage 2000; and US state.RESULTS: Five‐year net survival increased from 16.4% (95% confidence interval, 16.3%‐16.5%) for patients diagnosed 2001‐2003 to 19.0% (18.8%‐19.1%) for those diagnosed 2004‐2009, with increases in most states and among both blacks and whites. Between 2004 and 2009, 5‐year survival was lower among blacks (14.9%) than among whites (19.4%) and ranged by state from 14.5% to 25.2%.CONCLUSIONS: Lung cancer survival improved slightly between the periods 2001‐2003 and 2004‐2009 but was still low, with variation between states, and persistently lower survival among blacks than whites. Efforts to control well established risk factors would be expected to have the greatest impact on reducing the burden of lung cancer, and efforts to ensure that all patients receive timely and appropriate treatment should reduce the differences in survival by race and state. Cancer 2017;123:5079‐99. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
- Open Access
Disparities in ovarian cancer survival in the United States (2001‐2009): Findings from the CONCORD‐2 study
BACKGROUND: Ovarian cancer is the fifth leading cause of cancer death among women in the United States. This study reports ovarian cancer survival by state, race, and stage at diagnosis using data from the CONCORD‐2 study, the largest and most geographically comprehensive, population‐based survival study to date.METHODS: Data from women diagnosed with ovarian cancer between 2001 and 2009 from 37 states, covering 80% of the US population, were used in all analyses. Survival was estimated up to 5 years and was age standardized and adjusted for background mortality (net survival) using state‐specific and race‐specific life tables.RESULTS: Among the 172,849 ovarian cancers diagnosed between 2001 and 2009, more than one‐half were diagnosed at distant stage. Five‐year net survival was 39.6% between 2001 and 2003 and 41% between 2004 and 2009. Black women had consistently worse survival compared with white women (29.6% from 2001‐2003 and 31.1% from 2004‐2009), despite similar stage distributions. Stage‐specific survival for all races combined between 2004 and 2009 was 86.4% for localized stage, 60.9% for regional stage, and 27.4% for distant stage.CONCLUSIONS: The current data demonstrate a large and persistent disparity in ovarian cancer survival among black women compared with white women in most states. Clinical and public health efforts that ensure all women who are diagnosed with ovarian cancer receive appropriate, guidelines‐based treatment may help to decrease these disparities. Future research that focuses on the development of new methods or modalities to detect ovarian cancer at early stages, when survival is relatively high, will likely improve overall US ovarian cancer survival. Cancer 2017;123:5138‐59. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Open AccessDisparities in ovarian cancer survival in the United States (2001‐2009): Findings from the CONCORD‐2 study
BACKGROUND: Ovarian cancer is the fifth leading cause of cancer death among women in the United States. This study reports ovarian cancer survival by state, race, and stage at diagnosis using data from the CONCORD‐2 study, the largest and most geographically comprehensive, population‐based survival study to date.METHODS: Data from women diagnosed with ovarian cancer between 2001 and 2009 from 37 states, covering 80% of the US population, were used in all analyses. Survival was estimated up to 5 years and was age standardized and adjusted for background mortality (net survival) using state‐specific and race‐specific life tables.RESULTS: Among the 172,849 ovarian cancers diagnosed between 2001 and 2009, more than one‐half were diagnosed at distant stage. Five‐year net survival was 39.6% between 2001 and 2003 and 41% between 2004 and 2009. Black women had consistently worse survival compared with white women (29.6% from 2001‐2003 and 31.1% from 2004‐2009), despite similar stage distributions. Stage‐specific survival for all races combined between 2004 and 2009 was 86.4% for localized stage, 60.9% for regional stage, and 27.4% for distant stage.CONCLUSIONS: The current data demonstrate a large and persistent disparity in ovarian cancer survival among black women compared with white women in most states. Clinical and public health efforts that ensure all women who are diagnosed with ovarian cancer receive appropriate, guidelines‐based treatment may help to decrease these disparities. Future research that focuses on the development of new methods or modalities to detect ovarian cancer at early stages, when survival is relatively high, will likely improve overall US ovarian cancer survival. Cancer 2017;123:5138‐59. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.